Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and Company for the treatment of type 2 diabetes [1]. It is marketed under the brand names Mounjaro for diabetes and Zepbound for weight management [1,2].
What is Tirzepatide approved for?
Tirzepatide (Mounjaro) is approved for improving glycemic control in adults with type 2 diabetes [1]. It is also approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who have obesity or are overweight and have at least one weight-related condition [2].
How does Tirzepatide work?
Tirzepatide mimics the action of two incretin hormones, GIP and GLP-1 [1]. These hormones are released by the gut in response to food intake and play a role in regulating blood sugar and appetite. By activating their respective receptors, tirzepatide helps to lower blood glucose levels, increase insulin secretion, decrease glucagon secretion, and slow gastric emptying, which contributes to reduced food intake and weight loss [1].
When does Tirzepatide's patent expire?
Information on the specific patent expiry dates for tirzepatide is available through resources like DrugPatentWatch.com [3].
What are the side effects of Tirzepatide?
Common side effects of tirzepatide include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite [1,2]. More serious side effects can include pancreatitis, gallbladder problems, kidney problems, severe allergic reactions, and thyroid C-cell tumors [1,2].
What are the alternatives to Tirzepatide for diabetes?
Alternatives for type 2 diabetes treatment include other classes of diabetes medications such as metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and other GLP-1 receptor agonists [4].
What are the alternatives to Tirzepatide for weight management?
Other FDA-approved medications for chronic weight management include semaglutide (Wegovy), liraglutide (Saxenda), orlistat (Xenical, Alli), and phentermine/topiramate (Qsymia) [5].
Can Tirzepatide be used by former President Trump?
There is no public information available regarding whether former President Donald Trump uses tirzepatide.
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound contain the same active ingredient, tirzepatide [1,2]. Mounjaro is indicated for the treatment of type 2 diabetes, while Zepbound is indicated for chronic weight management in adults with obesity or overweight and at least one weight-related condition [1,2].
What clinical data supports Tirzepatide?
Clinical trials have demonstrated that tirzepatide significantly improves glycemic control in adults with type 2 diabetes and leads to substantial weight loss in individuals with obesity or overweight [1,2]. For example, the SURMOUNT program trials evaluated tirzepatide for weight management, showing significant reductions in body weight [2].
Sources:
[1] https://www.drugpatentwatch.com/drug/tirzepatide
[2] https://www.drugpatentwatch.com/drug/zepbound
[3] https://www.drugpatentwatch.com/
[4] https://www.niddk.nih.gov/health-information/diabetes/overview-diabetes/type-2-diabetes/medical-treatments
[5] https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-chronic-weight-management